The director of Quramax Medikal, Singh Ragvendra Pratar, admitted at the Doc-1 Max trial that he gave $33,000 to an employee of the State Expertise and Medicine Standardization Center so that they would not conduct an inspection check before registering the Kurarax drug. This drug was eventually registered in Uzbekistan. The defendant said that this sum first amounted to $45,000, and then decreased to $33,000. According to him, Zh. E., who worked at the State Expertise and Medicine Standardization Center at the Pharmaceutical Agency, asked for the money. The head of Quramax later admitted that he had given J. E. $33,000 to stop the inspection of Marion Biotech PVT. Ltd (India). According to the indictment, Marion Biotech planned to sell Curarax 200 and Curarax 400 in Uzbekistan. An application for registration was submitted to the Center. However, the documents required for registration of the drug, as well as the documents of “Doc-1 Max”, “were unreliable, incomplete and not notarized.” The director of Quramax Medikal, Ragnevdra Pratar, stated that he handed over the money to Zh.E. near the Oybek metro station. According to the defendant, Zh. E. promised that the inspection would not come for a check in August. Marion Biotech antibacterial drugs Kurarax 200, Kurarax 400 and Kurarax Orni were registered on May 25 (the day before the meeting of the scientific council) and July 19, 2022, according to the Gazeta.uz did in the State Register of Medicines and Medical Devices. 65 children have died after taking medicines from Indian Marion Biotech in Uzbekistan. The State Security Service announced the initiation of a criminal case into the death of children at the end of December and the detention of officials of the importing company Quramax Medical and the Center for Medicine Standardization.
Source: Central Asian News Services